{"id":11459,"date":"2023-11-09T03:37:19","date_gmt":"2023-11-09T03:37:19","guid":{"rendered":"https:\/\/infundpros.com\/news\/ideal-pairs-trade-into-2024-health-vs-hype\/"},"modified":"2023-11-09T03:37:20","modified_gmt":"2023-11-09T03:37:20","slug":"ideal-pairs-trade-into-2024-health-vs-hype","status":"publish","type":"post","link":"https:\/\/infundpros.com\/?p=11459","title":{"rendered":"Ideal Pairs Trade Into 2024: Health Vs. Hype"},"content":{"rendered":"
\n

<\/picture>
<\/figcaption><\/figure>\n<\/p>\n

Re-Rating Healthcare Amidst Stagflation and Technology Vulnerabilities<\/strong><\/h2>\n

The Political Shift and Its Implications on Healthcare<\/strong><\/h4>\n

Historically, the biotech and health index has endured periods of underperformance; we believe a substantial reason driving the healthcare stocks to underperform can be attributed to the overhang of government intervention. Particularly, policies such as the IRA capping drug price increases and potential governmental contracts have exerted downward pressure on the earnings of big pharma and biotech companies. This has been further accentuated by the Democratic administration’s approach towards these industries. However, recent <\/span>polling data suggests a potential reversal in this trend. Indications of a probable Republican win point towards a possible policy revision, especially those that the Democratic regime has been arduously pushing for. Such a political reshuffling, if it transpires, could prove to be the wind beneath the wings of the healthcare sector. The end of 2023 and 2024 might just turn out to be pivotal years wherein the market could re-rate healthcare stocks, paving the way for a substantial upside.<\/span><\/span><\/p>\n

\n

\"538<\/span>
\n

538 poll data (538 poll data)<\/p>\n<\/figcaption><\/figure>\n<\/p>\n

Stagflation Fears and Its Differential Impact on Tech vs. Healthcare<\/strong><\/h2>\n

An emergent concern on the economic horizon is the specter of stagflation. The Federal Reserve’s stance of maintaining a high-interest rate, coupled with persistent inflation, is setting the stage for such an economic scenario. This is further exacerbated by geopolitical tensions in regions like Ukraine and Israel, which have a direct bearing on global oil and commodity prices. In such a backdrop, the technology sector appears particularly vulnerable. A significant portion of tech companies derive their revenues from consumer discretionary services. For instance, during economic recessions or periods of reduced disposable incomes, non-essential services like Netflix subscriptions can be the first to face the consumer’s axe. In contrast, the healthcare sector boasts of inherent resilience. Irrespective of economic conditions, patients necessitate medicines, offering a non-discretionary nature to healthcare revenues. Even if the US IRA holds its policies, it will likely allow pharmaceutical companies to adjust prices in tandem with inflation. Thus, healthcare not only presents robust growth prospects but also positions itself as a potent hedge against inflation.<\/p>\n

The M&A Dynamics in Biotech and Contrasting Tech Valuations<\/strong><\/h2>\n

Biotech M&A activity has been on the ascent, and the premiums attached to these transactions are witnessing a northward journey. This trend stands in stark contrast to the biotech index, XBI, which is currently languishing at near-historic lows. This divergence presents a compelling risk-reward proposition for potential investors in the biotech space. On the other hand, tech ETFs are hovering close to their all-time highs. A considerable impetus for this rally has been the euphoria surrounding Artificial Intelligence, which has catapulted stocks like NVIDIA (NVDA) to stratospheric levels. While AI undeniably offers immense growth potential, the current valuations pose questions about the sustainability of such lofty prices, especially when juxtaposed with the aforementioned macroeconomic concerns.<\/p>\n

\n

\"Chart\"
Data by YCharts<\/figcaption><\/figure>\n
\"Biopharmadive\"<\/span>
\n

Biopharmadive database (Biopharmadive)<\/p>\n<\/figcaption><\/figure>\n<\/p>\n

Why Short ARKK\/QQQ for Tech Downturn?<\/strong><\/h2>\n

ARKK (ARK Innovation ETF) and QQQ (Invesco QQQ Trust)<\/em> are some of the most well-known ETFs that track the technology sector and broader innovative companies.<\/p>\n

    \n
  1. \n

    ARKK’s Exposure:<\/strong> ARKK is heavily invested in disruptive technologies and companies that are believed to be leading innovation in their respective fields. Companies in ARKK’s portfolio include Tesla, Roku, and Square, which have seen exponential growth but are vulnerable during economic downturns due to their high valuations.<\/p>\n<\/li>\n

  2. \n

    QQQ’s Exposure:<\/strong> QQQ tracks the NASDAQ-100 index, which consists of 100 of the largest non-financial companies listed on the NASDAQ stock exchange. This makes QQQ more concentrated in tech with companies like Apple, Microsoft, and Amazon.<\/p>\n<\/li>\n<\/ol>\n

    Pros of Shorting ARKK\/QQQ:<\/strong><\/p>\n